Publications & Presentations

To learn more about our innovative technology:

A Long Term, Open Label Study of Safety and Tolerability of Precision Olfactory Delivery of DHE in Acute Migraine (STOP 301): Clinical Results

Selected as a live presentation at the 2020 Migraine Trust International Symposium Authors: Sheena Aurora, Maria Jeleva, Jasna Hocevar-Trnka, John Hoekman, Stephen Shrewsbury Introduction: Migraine is a common neurological disease impacting at least 12% of the US population. Despite several…

Does Dihydroergotamine Treat the “Whole Migraine”?

Presented at the 2020 Migraine Trust International Symposium Authors: Sheena Aurora, Sutapa Ray, Kelsey Satterly, Stephen Shrewsbury, John Hoekman Introduction: Migraine is recognized as a complex, multifactorial brain network disease associated with 40 different gene loci. Despite a growing body…

Patient Acceptability of a Novel Upper Nasal Delivery System for DHE – Using the Precision Olfactory Delivery (POD®) Device (INP104)

Presented at the 2020 Migraine Trust International Symposium Authors: Stephen Shrewsbury, Sheena Aurora, John Hoekman, Maria Jeleva Introduction: DHE is an effective acute treatment for episodic migraine, but from 1946–1996 was only available as an injection. Nasal DHE (Migranal® )…

1 2 3